When Ariana Pharma announced this summer that the WIN Consortium had chosen it to develop new personalized cancer medicine software through the consortium’s WINTHER trial, it wasn’t just a validation of Paris-based Ariana’s data management skills in life science, notes Dr. David Morley, Ariana’s vice president of computational technology — it was also a sign […]
The advent of targeted cancer therapies has necessitated the development of companion diagnostics to identify those patients whose genetic makeup will allow them to benefit. But a patient’s gene signature is only one factor of many capable of affecting their response to a treatment. There is a demand, says Mohammad Afshar, CEO of Ariana Pharma, […]